Business Strategy
Anat Cohen-Dayag explains how Compugen transformed from computational service provider to clinical-stage biotech by integrating AI with biology and structuring strategic pharma collaborations.
By offering free sequencing and embracing radical openness with global partners, Regeneron Genetics Center has gathered over 3 million samples, leading to the identification of over 30 drug targets now in Regeneron’s pipeline.
EY's Arda Ural joins In Vivo to discuss the long-awaited recovery in biotech IPOs, the evolving capital markets landscape and how tariffs and TrumpRx are reshaping biopharma supply chains.
Juby Jacob-Nara outlines her vision for expanding biosimilar uptake and leveraging policy changes to improve patient access.
French biotech CellProthera is advancing to Phase III with its autologous CD34+ stem cell therapy that regenerates tissue after severe heart attacks.
Memo Therapeutics is sharpening its focus on its lead antibody Potravitug, for BK polyomavirus (BKPyV) in kidney transplant patients as it prepares for Phase III trials and doubles down on patient engagement.
Patient advocacy organizations are transforming gene therapy development by funding research, de-risking programs and driving ultra-rare disease treatments from concept to clinic at unprecedented speed.
Abivax reflects on a transformative year marked by landmark clinical success and ambitious plans for the future.
New York biotech OS Therapies reported 75% two-year survival in an osteosarcoma trial of its immunotherapy, OST-HER2. Leadership is targeting early 2026 approvals across three continents for what is the first new osteosarcoma treatment in 40 years.
Pharma business development teams are adapting M&A and licensing strategies amid market volatility and looming patent cliffs.
Strategic partnerships and disciplined spending are emerging as key survival tools in challenging funding environment.
The neuromodulation space is quickly filling with well-funded companies that have demonstrated early signs of success. However, with strategics seemingly unwilling to spend on novel technologies and pharma desperate to maintain its foothold in CNS, these companies will face many challenges.
Eight $1bn+ alliances were penned in September, and four exceeded $2bn. In the top alliance by deal value, Monte Rosa Therapeutics will apply its AI-enabled QuEEN platform for the discovery and development of novel molecular glue degraders for immune-mediated diseases.
MediciNova and Coya Therapeutics are advancing ALS candidates as regulatory flexibility and Phase II pipeline concentration create a pivotal market inflection point.
The EU is diversifying its trading partners, which means that new markets may open up to the pharmaceutical industry, countering transatlantic tensions.
An extensive list of blockbuster drugs face patent expiry over the next six years, putting significant revenues at risk for major companies. While Eli Lilly and Novo Nordisk are reaping the rewards of GLP-1 successes, other large pharmas face steep challenges in closing their growth gaps.
Tris Pharma may be making headlines for its novel pain medication cebranopadol, but the New Jersey-based company's story extends far beyond a single asset.
Boehringer Ingelheim's collaboration with Re-Vana Therapeutics is the most recent step in the German pharma’s paradigm shift toward earlier intervention in retinal diseases.
In the near future, “the US may no longer hold its position as the most important market,” says the CEO of a UK-based emerging biotech firm. Today’s biotech companies are shifting their growth strategies dramatically – moving away from reliance on a single dominant market.
For months, US Health and Human Services Secretary Robert F. Kennedy Jr. had talked about banning direct-to-consumer television ads for prescription drugs. And now, he is making good on his promise – but in a roundabout way.